Information Provided By:
Fly News Breaks for February 21, 2017
ANAB
Feb 21, 2017 | 06:30 EDT
Credit Suisse analyst Dr. Kennen MacKay initiated AnaptysBio with an Outperform and a $34 price target saying it is an emerging pre-commercial antibody platform company with two lead assets targeting diseases of inflammation. ANB020 and ANB019 are currently in early-stage trials with multiple re-risking catalysts expected in 2017-1H 2018. The analyst said AnaptysBio's development capabilities as externally validated based on partnerships with Tesaro(TSRO) and Celgene (CELG).
News For ANAB From the Last 2 Days
There are no results for your query ANAB
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.